Masaru Miyagi

Prof. Masaru Miyagi

Department of Pharmacology, Case Western Reserve University, Wood Building, W151D, 10900 Euclid Ave, Cleveland, OH 44106, USA
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2006 in Mass Spectrometry Reviews
Verified
Journal Article
Closed access
PDF file
Masaru MiyagiMasaru Miyagi
Masaru Miyagi
KRK.C. Sekhar Rao
K.C. Sekhar Rao

1 July 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CKChandra Sekhar Rao Kadiyala
Chandra Sekhar Rao Kadiyala
LZLing Zheng
Ling Zheng
YDYunpeng Du
Yunpeng Du
EYElizabeth Yohannes
Elizabeth Yohannes
HKHung-Ying Kao
Hung-Ying Kao
TKTimothy S. Kern
Timothy S. Kern
Histone acetylation was significantly increased in retinas from diabetic rats, and this acetylation was inhibited in diabetics treated with minocycline, a drug known to inhibit early diabetic retinopathy in animals. Histone acetylation and expression of inflammatory proteins that have been implicated in the pathogenesis of diabetic retinopathy were increased likewise in cultured retinal Müller glia grown in a diabetes-like concentration of glucose. Both the acetylation and induction of the inflammatory proteins in elevated glucose levels were significantly inhibited by inhibitors of histone acetyltransferase (garcinol and antisense against the histone acetylase, p300) or activators of histone deacetylase (theophylline and resveratrol) and were increased by the histone deacetylase inhibitor, suberolylanilide hydroxamic acid. We conclude that hyperglycemia causes acetylation of retinal histones (and probably other proteins) and that the acetylation contributes to the hyperglycemia-induced up-regulation of proinflammatory proteins and thereby to the development of diabetic retinopathy.

30 July 2008 in Analytical Chemistry
Verified
Journal Article
Closed access
Masaru MiyagiMasaru Miyagi
Masaru Miyagi
TNTakashi Nakazawa
Takashi Nakazawa

1 September 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YYYiyuan Yuan
Yiyuan Yuan
CKChandra S. Kadiyala
Chandra S. Kadiyala
TCTsui-Ting Ching
Tsui-Ting Ching
PHParvin Hakimi
Parvin Hakimi
SSSudipto Saha
Sudipto Saha
ZFZhaoyang Feng
Zhaoyang Feng
Caloric restriction (CR) markedly extends life span and improves the health of a broad number of species. Energy metabolism fundamentally contributes to the beneficial effects of CR, but the underlying mechanisms that are responsible for this effect remain enigmatic. A multidisciplinary approach that involves quantitative proteomics, immunochemistry, metabolic quantification, and life span analysis was used to determine how CR, which occurs in the Caenorhabditis elegans eat-2 mutants, modifies energy metabolism of the worm, and whether the observed modifications contribute to the CR-mediated physiological responses. A switch to fatty acid metabolism as an energy source and an enhanced rate of energy metabolism by eat-2 mutant nematodes were detected. Life span analyses validated the important role of these previously unknown alterations of energy metabolism in the CR-mediated longevity of nematodes. As observed in mice, the overexpression of the gene for the nematode analog of the cytosolic form of phosphoenolpyruvate carboxykinase caused a marked extension of the life span in C. elegans, presumably by enhancing energy metabolism via an altered rate of cataplerosis of tricarboxylic acid cycle anions. We conclude that an increase, not a decrease in fuel consumption, via an accelerated oxidation of fuels in the TCA cycle is involved in life span regulation; this mechanism may be conserved across phylogeny.

2 January 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
AAAbhishek Ajay
Abhishek Ajay
HWHan Wang
Han Wang
ARAli Rezvani
Ali Rezvani
OSOmid Savari
Omid Savari
BGBrandon J. Grubb
Brandon J. Grubb
ADAfshin Dowlati
Afshin Dowlati
Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, including systemic toxicity, acquired resistance, and the lack of reliable biomarkers for patient selection. To enhance the effectiveness of ADC therapies in SCLC, we focused on target selection in this study by investigating the expression of ADC targets - SEZ6, DLL3, CD276, and TACSTD2 - in cell lines and patient samples. SEZ6 expression was significantly elevated in various SCLC transcriptional subtypes, particularly ASCL1, and exhibited gender-specific differences, being lower in women. DLL3 was primarily observed in the ASCL1 subtype, while CD276 showed high expression in non-neuroendocrine subtypes. TACSTD2 levels were generally low and attenuated in lymph nodes and brain metastases compared to primary tumors. Our findings underscore the importance of understanding target expression patterns to optimize ADC therapy and advance precision medicine in SCLC treatment.

6 November 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JWJohn Paul Wanner
John Paul Wanner
RSRoopashree Subbaiah
Roopashree Subbaiah
YSYelenna Skomorovska-Prokvolit
Yelenna Skomorovska-Prokvolit
YSYousef Shishani
Yousef Shishani
EBEric Boilard
Eric Boilard
RGReuben Gobezie
Reuben Gobezie
Introduction: The development of effective treatments for osteoarthritis (OA) has been hampered by a poor understanding of OA at the cellular and molecular levels. Emerging as a disease of the 'whole joint’, the importance of the biochemical contribution of various tissues, including synovium, bone and articular cartilage, has become increasingly significant. Bathing the entire joint structure, the proteomic analysis of synovial fluid (SF) from osteoarthritic shoulders offers a valuable 'snapshot’ of the biologic environment throughout disease progression. The purpose of this study was to identify differentially expressed proteins in early and late shoulder osteoarthritic SF in comparison to healthy SF. Methods: A quantitative 18O labeling proteomic approach was employed to identify the dysregulated SF proteins in early (n = 5) and late (n = 4) OA patients compared to control individuals (n = 5). In addition, ELISA was used to quantify six pro-inflammatory and two anti-inflammatory cytokines. Results: Key results include a greater relative abundance of proteins related to the complement system and the extracellular matrix in SF from both early and late OA. Pathway analyses suggests dysregulation of the acute phase response, liver x receptor/retinoid x receptor (LXR/RXR), complement system and coagulation pathways in both early and late OA. The network related to lipid metabolism was down-regulated in both early and late OA. Inflammatory cytokines including interleukin (IL) 6, IL 8 and IL 18 were up-regulated in early and late OA. Conclusions: The results suggest a dysregulation of wound repair pathways in shoulder OA contributing to the presence of a 'chronic wound’ that progresses irreversibly from early to later stages of OA. Protease inhibitors were downregulated in late OA suggesting uncontrolled proteolytic activity occurring in late OA. These results contribute to the theory that protease inhibitors represent promising therapeutic agents which could limit proteolytic activity that ultimately leads to cartilage destruction.